U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 5 of 5 results

Status:
US Approved Rx (2018)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichi...
Status:
US Previously Marketed
First approved in 1995

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ceftibuten is a 3rd generation cephalosporin that is FDA approved for the treatment of acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis. Ceftibuten exerts its bactericidal action by bindin...
Status:
US Approved Rx (2018)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichi...
Status:
US Approved Rx (2018)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichi...
Status:
US Previously Marketed
First approved in 1995

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ceftibuten is a 3rd generation cephalosporin that is FDA approved for the treatment of acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis. Ceftibuten exerts its bactericidal action by bindin...